PharmaEssentia appoints Sunil Shah as U.S. general counsel  

PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taipei, Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Sulin Shah (pictured) as U.S. general counsel and head of compliance. Shah’s robust industry experience will guide U.S. infrastructure growth and capability building.

Prior to joining PharmaEssentia, Shah served as U.S. general counsel at Orphazyme where he supported extensive U.S. organisational and infrastructure development. Prior to Orphazyme, Shah was lead counsel in U.S. Hematology for Takeda, following the acquisition of Shire. Earlier in his career, he served in private legal practice and management consulting roles in Chicago.